Data Sheet

Product Name:	S55746
Cat. No.:	CS-0065115
CAS No.:	1448584-12-0
Molecular Formula:	C43H42N4O6
Molecular Weight:	710.82
Target:	Bcl-2 Family
Pathway:	Apoptosis
Solubility:	H2O : < 0.1 mg/mL (insoluble); DMSO : 50 mg/mL (70.34 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

S55746 (BLC201) is a potent, orally active and selective **BCL-2** inhibitor, with a K_i of 1.3 nM and a K_d of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity[1]. IC50 & Target: Ki: 1.3 nM (BCL-2)[1]. **In Vitro:** S55746 (0-1 μM) potently and selectively induces cell death[1].

S55746 selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner[1]. **In Vivo:** S55746 is a highly efficacious and well-tolerated (even at doses up to 300 mg/kg) orally active BCL-2 inhibitor [1].

S55746 (20-100 mg/kg, p.o.) inhibits xenograft growth in RS4;11 and Toledo models time- and dose-dependently[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: [1]Cells are seeded into 96-well plates and treated at 8 points with **1:2 serial dilution of S55746**. Cell viability is assessed and assayed for viability using CellTiter-Glo reagent. Plates are read using luminescence plate reader. Results are normalized to the viability of cells without **S55746** (control wells). The IC_{50} values are calculated using nonlinear regression algorithms in XCell software [1].

Animal Administration: [1]Mice[1]

Experiments are performed in **SCID/beige female mice**. RS4;11 Acute Lymphoblastic Leukemia cell lines and human cell lines are used. For each experiment, female SCID/beige mice are implanted subcutaneously with 3×10^6 Toledo or RS4;11. Body weights are recorded and tumors are measured with digital calipers twice to three times a week. When tumors reached approximately 200 mm^3 for efficacy studies or 300 mm^3 for pharmacodynamics studies, mice are randomized. **S55746** is formulated in PEG300/EtOH/water (40/10/50). Mice are treated via oral gavage at 10 mL/kg with different doses (e.g., **S55746: 20, 50, 100 mg/kg**)[1].

References:

[1]. Casara P, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018 Apr 13;9(28):20075-20088.

CAIndexNames:

1-Indolizinecarboxamide, 3-[6-[[(3S)-3,4-dihydro-3-(4-morpholinylmethyl)-2(1H)-isoquinolinyl]carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-N-(4-hydroxyphenyl)-N-phenyl-

SMILES:

O=C(C1=C2CCCCN2C(C3=C(C(N4CC5=C(C=CC=C5)C[C@H]4CN6CCOCC6)=O)C=C(OCO7)C7=C3)=C1)N(C8=CC=C(O)C=C8)C9=CC=CC=C9

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA